Adele Mourad , Rona McGeer , Emma Gray , Anna-Marie Bibby-Jones , Heather Gage , Lidia Salvaggio , Vikki Charles , Natasha Sanderson , Margaret O’Sullivan , Thomas Bird , Sumita Verma
{"title":"A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness","authors":"Adele Mourad , Rona McGeer , Emma Gray , Anna-Marie Bibby-Jones , Heather Gage , Lidia Salvaggio , Vikki Charles , Natasha Sanderson , Margaret O’Sullivan , Thomas Bird , Sumita Verma","doi":"10.1016/j.jhepr.2024.101183","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & Aims</h3><div>Only a handful of countries are on target to achieve elimination of HCV by 2030. People experiencing homelessness (PEH) remain an important HCV reservoir. The END C study evaluated clinical, patient reported, and health economic outcomes of a decentralised integrated model.</div></div><div><h3>Methods</h3><div>This prospective study assessed a decentralised regional service based at multiple homeless sites in southeast England. Novel linkage-care strategies were used. We assessed generic and liver specific health-related quality of life (HRQoL) (SF-12v2; EQ-5D-5L, and SFLDQol) pre-/post-HCV treatment, and cost per HCV case detected and cured. The primary outcome was sustained virological response (SVR12) in the intention-to-treat (ITT) population.</div></div><div><h3>Results</h3><div>We recruited 418 individuals with mean age 44.45 ± 10.6 years, 78% were male, 74% were currently homeless, current injecting drug use or alcohol use was 25% and 65%, respectively. Prevalence of cirrhosis (liver stiffness measurement ≥12 kPa) was 12%. A total of 28% (n = 116) were HCV PCR-positive of whom 105 individuals received direct acting antiviral treatment. The ITT SVR12 rates were 81% (95% CI 72%–88%), the only predictor of SVR12 was >80% treatment adherence (OR 20.69, 95% CI 6.227–68.772, <em>p <</em>0.001). HRQoL improved significantly after SVR12: SF-12v2 (General Health, Mental Health, Social Functioning, Mental Health Composite Score <em>p <</em>0.049); SFLDQoL (Symptoms/Effects of Liver Disease, Distress, Loneliness <em>p <</em>0.004) and EQ-5D-5L (Index Score, Visual Analog Scale <em>p <</em>0.001). Costs (British pound 2022) per HCV case detected and per case cured were £359 and £257, respectively. Reinfection rates were 6.82/100 person years.</div></div><div><h3>Conclusion</h3><div>The END C study endorses a multisite decentralised service for PEH enabling excellent linkage to care, high SVR12 rates, and significant improvements in generic and liver specific HRQoL, all being achieved at modest costs. Such services are paramount to help achieve HCV elimination.</div></div><div><h3>Impact and implications:</h3><div>In people experiencing homeless, we found a high prevalence of HCV, alcohol, and substance misuse including overdoses and mental health issues. Despite this, an integrated and decentralised service resulted in excellent linkage to care with high SVR12 rates. Even in this complex cohort with multiple comorbidities, SVR12 was associated with significant improvements in both generic and liver specific HRQoL. This was all achieved at modest costs in a community setting. Such models of care are feasible, easy to replicate, and essential if we are to achieve HCV elimination.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101183"},"PeriodicalIF":9.5000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHEP Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589555924001873","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & Aims
Only a handful of countries are on target to achieve elimination of HCV by 2030. People experiencing homelessness (PEH) remain an important HCV reservoir. The END C study evaluated clinical, patient reported, and health economic outcomes of a decentralised integrated model.
Methods
This prospective study assessed a decentralised regional service based at multiple homeless sites in southeast England. Novel linkage-care strategies were used. We assessed generic and liver specific health-related quality of life (HRQoL) (SF-12v2; EQ-5D-5L, and SFLDQol) pre-/post-HCV treatment, and cost per HCV case detected and cured. The primary outcome was sustained virological response (SVR12) in the intention-to-treat (ITT) population.
Results
We recruited 418 individuals with mean age 44.45 ± 10.6 years, 78% were male, 74% were currently homeless, current injecting drug use or alcohol use was 25% and 65%, respectively. Prevalence of cirrhosis (liver stiffness measurement ≥12 kPa) was 12%. A total of 28% (n = 116) were HCV PCR-positive of whom 105 individuals received direct acting antiviral treatment. The ITT SVR12 rates were 81% (95% CI 72%–88%), the only predictor of SVR12 was >80% treatment adherence (OR 20.69, 95% CI 6.227–68.772, p <0.001). HRQoL improved significantly after SVR12: SF-12v2 (General Health, Mental Health, Social Functioning, Mental Health Composite Score p <0.049); SFLDQoL (Symptoms/Effects of Liver Disease, Distress, Loneliness p <0.004) and EQ-5D-5L (Index Score, Visual Analog Scale p <0.001). Costs (British pound 2022) per HCV case detected and per case cured were £359 and £257, respectively. Reinfection rates were 6.82/100 person years.
Conclusion
The END C study endorses a multisite decentralised service for PEH enabling excellent linkage to care, high SVR12 rates, and significant improvements in generic and liver specific HRQoL, all being achieved at modest costs. Such services are paramount to help achieve HCV elimination.
Impact and implications:
In people experiencing homeless, we found a high prevalence of HCV, alcohol, and substance misuse including overdoses and mental health issues. Despite this, an integrated and decentralised service resulted in excellent linkage to care with high SVR12 rates. Even in this complex cohort with multiple comorbidities, SVR12 was associated with significant improvements in both generic and liver specific HRQoL. This was all achieved at modest costs in a community setting. Such models of care are feasible, easy to replicate, and essential if we are to achieve HCV elimination.
期刊介绍:
JHEP Reports is an open access journal that is affiliated with the European Association for the Study of the Liver (EASL). It serves as a companion journal to the highly respected Journal of Hepatology.
The primary objective of JHEP Reports is to publish original papers and reviews that contribute to the advancement of knowledge in the field of liver diseases. The journal covers a wide range of topics, including basic, translational, and clinical research. It also focuses on global issues in hepatology, with particular emphasis on areas such as clinical trials, novel diagnostics, precision medicine and therapeutics, cancer research, cellular and molecular studies, artificial intelligence, microbiome research, epidemiology, and cutting-edge technologies.
In summary, JHEP Reports is dedicated to promoting scientific discoveries and innovations in liver diseases through the publication of high-quality research papers and reviews covering various aspects of hepatology.